Antibiotic Stewardship

An industry Declaration on Antimicrobial Resistance (AMR) was announced at the World Economic Forum in Davos, Switzerland on January 20th 2016. Pfizer along with 85 companies and 9 associations, from 18 different countries signed the declaration. The Declaration sounds a strong call-to-action for governments and industry to collaborate on antibiotic stewardship policies; access to AMR educational materials, and new R&D incentives, such as IP mechanisms, and to support research and development of new products to treat and prevent infections.

http://www.pfizer.com/files/about/Position-Antimicrobial-Resistance.pdf.
Accessed August 2016

 

Pfizer is also working with other nongovernmental organizations (NGOs) such as the Gates Foundation to develop effective stewardship strategies for the developing world.

Antibiotic stewardship programs are designed to mitigate the development and impact of antimicrobial resistance but will not eliminate the issue. Pfizer is working to help ensure successful and judicious antibiotic use through our efforts in medical education and global resistance monitoring. Pfizer has made significant investment in infectious disease research and development, focusing currently on preventive vaccines. Pfizer continues to maintain surveillance programs that report in vitro activity of clinical bacterial isolates searchable regions, bacteria type, type of infection, etc.

 

Pfizer partnered with the British Society for Antimicrobial Chemotherapy and the University of Dundee to launch the Massive Open Online Course (MOOC) on antimicrobial stewardship. The course helps health care professionals understand and address the global threat of antimicrobial resistance, focusing on how to responsibly use high-quality antibiotics safely in everyday practice. As of December 2015, over 5,000 healthcare professionals had completed the course, with over 15,000 registrants.

 

Regional and global surveillance of antibiotic resistance patterns provides physicians with important information to choose the most effective antibiotics and to plan and assess stewardship and strategies. Pfizer sponsors three AMR surveillance program called ATLAS.  The goal of this program is to provide resistance information regarding Pfizer products and other antibiotics so that physicians can make the most appropriate choices for their patients. It also allows us to assess stewardship and access.
 

ATLAS has expanded to include the new assets acquired from AZ and has incorporated all of the previous AMS programs, including TEST, ZAAPS and LEADER.

 

Pfizer’s global stand on responsible use of anti-infectives

Pfizer takes an active leadership role in the responsible stewardship of antimicrobials use by the medical community. This commitment to the appropriate use of anti-infectives has remained a priority throughout a long history of anti-infective innovation, both by Pfizer and its predecessor companies.

At the core of Pfizer’s effort against resistance are ongoing global surveillance programs. The programs continuously monitor the in-vitro activity of Pfizer’s anti-infective portfolio around the world, to provide susceptibility and resistance updates to the medical community, including issues related to Zyvox: 

  • Pfizer has tracked activity of ZYVOX against non-USA Gram-positive pathogens for 11 consecutive years, through the ZYVOX Annual Appraisal of Potency and Spectrum (ZAAPS)1
  • From 2010 to 2012, ZAAPS tested the ZYVOX susceptibility of more than 10,836 Staphylococcus aureus strains from 73 medical centres in 33 countries1
  • Since 2004, Pfizer has surveyed in vitro activity of tigecycline and its comparators against pathogens from 200 sites in 69 countries. Results from the Tigecycline Evaluation and Surveillance Trial (TEST) are searchable by region, agent, and pathogen, at http://www.testsurveillance.com.  Accessed August 2016

 

A commitment to expanding knowledge about Anti-Infectives

Pfizer will continue to share information on ZYVOX® (linezolid). Pfizer takes an active leadership role regarding the responsible use of antibiotics and will continue to devote significant resources to supporting healthcare professionals in improving the way in which infectious diseases are managed.

To help inform clinical decision, Pfizer Medical information can provide accurate clinical and scientific information about Pfizer products upon request.  Please see more contact information under Contact Us at the bottom of the page.

 

 

References

1. Mendes RA, et al. J Antimicrob Chemother 2014;69:1582–8.

Minimum Data Sheet ZYVOX®

(linezolid 2mg/mL, 600 mg, 20 mg/mL) injection, tablets, granules for oral suspension. Indications: Infections due to susceptible organisms, including those associated with concurrent bacteraemia. No clinical activity against Gram-negative pathogens. Contraindications: Hypersensitivity; monoamine oxidase inhibitors; potential interactions producing elevations of blood pressure; potential serotonergic interactions. Precautions: Monitor blood in certain populations. Reports of serotonin syndrome when co-administered with serotonergic agents. Antibiotic associated pseudomembranous colitis. Symptoms of visual impairment; monitor visual function. Convulsions (rare). Safety and effectiveness following 28 days not established. Gramnegative pathogens. Caution in patients with severe renal and hepatic insufficiency. Pregnancy. Category B3. Use only if the benefit outweighs the risk. Lactation. Discontinue. Interactions. Tyramine; serotonergic agents; vasopressive / dopaminergic agents; rifampicin. Adverse Effects: Headache, candidiasis; taste perversion; GI disturbances. Peripheral and optic neuropathy. Lactic acidosis, angioedema, rash, myelosuppression, bullous skin disorders and serotonin syndrome (very rare). Abnormal haematology and liver function tests. Dosage and Administration: IV (30-120 min infusion) or oral bid (with or without food). Adults. CAP/nosocomial pneumonia: 600 mg IV or orally for 10 to 14 days. Skin and soft tissue infections: 400 mg to 600 mg orally or 600 mg IV for 10 to 14 days. Enterococcal infections: 600 mg IV or orally for 14 to 28 days. Children and adolescents. Community acquired/nosocomial pneumonia and SSTI: 10 mg/kg IV or orally once every 8 hours for 10 to 14 days. Enterococcal infections: 10 mg/kg IV or orally once every 8 hour for 14 to 28 days. Neonates. Refer to full Datasheet for dosage instructions. Medicine Classification: Prescription Medicine Pfizer New Zealand Ltd, PO Box 3998, Auckland, New Zealand, 1140 Date of preparation: 31 March 2010 Based on the Data Sheet of 22 March 2010 Before prescribing, please review Data Sheet available from Medsafe (www.medsafe.govt.nz) or Pfizer New Zealand Ltd(www.pfizer.co.nz) or call 0800 736 363. ® Registered Trademark